Author: Ravi Shankar

ABN AMRO posts net profit of € 940 million in Q3 2026 

11 November 2026

Key messages

• Net profit increased by 52% year-on-year to € 940 million, bringing the year-to-date return on equity to 12.5%
• Continued business momentum, with growth in both lending and deposits and NIBC contributing from 1 August
• Strong net interest income (NII), supported by the favourable interest rate environment; commercial NII guidance further raised to above € 6.9 billion for 2026
• Continued delivery on cost reductions; guidance for the year unchanged at € 5.5 billion
• Sound credit quality, with € 11 million in net impairment releases; individual impairments were offset by model-related releases
• CET1 ratio of 15.3%, reflecting the acquisition of NIBC and continued capital optimisation

Marguerite Bérard, CEO:

‘ABN AMRO delivered another strong quarter, characterised by solid commercial momentum, net impairment releases and further progress on our strategic priorities.   

The Dutch economy remained resilient, supported by domestic demand. Inflation rose as energy prices increased. In response to these inflationary pressures, the ECB raised its deposit rate by 25 basis points to 2.50% in September. The housing market continues to be supported by sound fundamentals, although higher interest rates are expected to temper activity. In this environment, we remain focused on supporting our clients as they navigate economic, geopolitical and cybersecurity-related uncertainty.

In the third quarter of 2026, ABN AMRO delivered a net profit of € 940 million, with NIBC contributing following its inclusion from 1 August. NIBC strengthens our position in mortgages (€ 15 billion) and savings (€ 13 billion) and supports our ambition to create sustainable long-term value. Commercial NII increased by 7% this quarter and we have raised our guidance for full-year 2026 to above € 6.9 billion. Underlying costs increased as expected, and we remain on track to meet our full-year guidance of € 5.5 billion.

Our results show further progress on our three strategic priorities: right-sizing our cost base, delivering profitable growth and optimising our capital allocation.

Right-sizing our cost base

We further simplified the bank and improved our efficiency. The legal merger of ABN AMRO Hypotheken Group was completed, reducing complexity and creating a simpler, more streamlined organisation. Excluding the impact of the NIBC acquisition, our workforce continued to decline, although the pace of reduction slowed. With approximately 46% of our 2028 workforce reduction target already achieved, we remain on track.

We also advanced the modernisation of our technology landscape and client processes. The extension of our partnership with Infosys will help to further simplify and modernise our IT landscape, while accelerating the responsible adoption of AI across the company. In our anti-money laundering operations, for example, our AI solution Delphi supports analysts in carrying out risk assessments, improving efficiency and quality while preserving human judgement. These improvements make the bank easier to run and scale, and help colleagues spend more time on activities that create value for clients. 

Growing profitably

Personal & Business Banking increased net profit by 25% quarter-on-quarter, supported by the inclusion of NIBC. We expanded our savings offering with new products, giving clients greater choice in terms of flexibility, returns and certainty. For consumer clients, Quarterly Savings offers a variable bonus rate on savings held until the end of the quarter, while keeping funds readily accessible. Time-Lock Savings offers a more attractive variable rate with a minimum 45-day waiting period for withdrawals, and ABN AMRO MeesPierson introduced a similar solution for business clients. The completion of the sale of Alfam on 1 November and the legal merger of ABN AMRO Hypotheken Group into ABN AMRO in October mark further progress in simplifying and streamlining the P&BB business model.

Wealth Management continued to grow in the third quarter, with core net new assets approaching € 4.1 billion for the year to date, keeping us on track to deliver our annual growth ambition of € 5-7 billion. Simplification in Germany progressed as planned, with the successful sale of the real estate investment management portfolio and the recent IT migration of HAL’s wealth management activities.

We are proud to have been named the Netherlands’ Best Private Bank for Wealthy Women at the Global Private Banking Awards 2026. The award highlights our success in attracting female clients, one of our three key focus segments alongside entrepreneurs and the next generation.

Our dual-client approach is creating commercial opportunities by connecting the private and business needs of entrepreneurs and business owners, strengthening client relationships and enabling us to serve clients more comprehensively. One example is in Germany, where colleagues from Wealth Management and Clearing jointly developed a tailored solution that connects a client’s private and business assets, illustrating the strength of collaboration across our European franchise.

Corporate Banking delivered a good performance and increased lending to clients. This reflects our continued focus on disciplined, profitable growth and was further supported by net impairment releases. We continue to build on our strong relationships with corporate clients, including family-owned businesses, combining sector expertise with financing and advisory capabilities to support their growth and strategic ambitions.

Our financing and capital markets expertise also continued to support the European transition. During the quarter, we helped clients across Europe with renewable energy and critical infrastructure projects, including financing large-scale battery storage projects in Belgium and the UK. These projects help provide the flexibility needed for increasingly renewable electricity systems and demonstrate how we combine sector expertise with financing capabilities across markets.

In Clearing, we continued to innovate for our clients. ABN AMRO was the first bank to launch repo clearing as a standardised service, lowering barriers to secured liquidity and improving collateral management, while helping clients manage their balance sheets more efficiently.

Optimising our capital allocation

Excluding the increase in risk-weighted assets (RWA) from the inclusion of NIBC, RWA remained broadly stable. RWA increases from business developments, primarily in Corporate Banking and Clearing, were offset by asset quality improvements and methodological updates. We continued to optimise capital allocation across the bank, actively managing our portfolio and redeploying capital towards activities with attractive risk‑adjusted returns and structural growth opportunities.

On 7 October, the Dutch state announced a new trading programme to reduce its shareholding to 10.5%. This is the fifth such plan introduced since early 2023 as part of the gradual return to the market of ABN AMRO shares held by the Dutch state.

We enter the fourth quarter with good business momentum. Execution of our strategy is progressing across all three key priorities and, supported by the tailwind from the interest rate environment, we will update our targets next quarter.

Today, almost a year has passed since we announced our new strategy. I look back with pride on what we have already achieved and look ahead with confidence to the work still before us. I would like to thank our colleagues for the dedication they demonstrate every day in serving our clients. My thanks also go to our clients and investors for their continued trust and support.

  

This press release is published by ABN AMRO Bank N.V. and contains inside information within the meaning of article 7 (1) to (4) of Regulation (EU) No 596/2014 (Market Abuse Regulation).

Note for the editor, not for publication: 
ABN AMRO Press Office: +31 (0)20-6282160, Jarco de Swart, email: Jarco.de.swart@nl.abnamro.com.
ABN AMRO Investor Relations: +31 (0)20 6282282, John Heijning, email: investorrelations@nl.abnamro.com

Operating results

(in millions)	Q3 2026	Q3 2025	Change	Q2 2026	Change		Nine months 2026	Nine months 2025	Change
Net interest income	1,822	1,580	15%	1,700	7%		5,159	4,671	10%
Net fee and commission income	601	561	7%	617	-3%		1,826	1,561	17%
Other operating income	218	28		106	105%		367	226	62%
Operating income	2,641	2,169	22%	2,424	9%		7,351	6,458	14%
Personnel expenses	812	791	3%	789	3%		2,350	2,252	4%
Other expenses	593	617	-4%	511	16%		1,633	1,783	-8%
Operating expenses	1,405	1,409		1,300	8%		3,983	4,035	-1%
Operating result	1,235	761	62%	1,123	10%		3,368	2,423	39%
Impairment charges on financial instruments	-11	-49	76%	24			79	-49
Profit/(loss) before taxation	1,247	809	54%	1,100	13%		3,289	2,472	33%
Income tax expense	307	192	60%	319	-4%		876	630	39%
Profit/(loss) for the period	940	617	52%	781	20%		2,413	1,842	31%
Attributable to:
Owners of the parent company	939	617	52%	780	20%		2,412	1,842	31%
Non-controlling interests					16%		1
Other indicators
Net interest margin (NIM) (in bps)	157	149		149			152	151
Cost/income ratio	53.2%	64.9%		53.7%			54.2%	62.5%
Return on average equity¹	14.5%	9.5%		12.1%			12.5%	9.6%
Basic and diluted earnings per share (in €)2, 3	1.09	0.67		0.90			2.77	2.03
Shareholder’s equity per share (in €)	29.99	28.07		29.58
Client assets (end of period, in billions)	434.8	389.8		415.0
Number of employees (end of period, in FTEs)	25,157	25,920		24,561
– of which internal employees	23,408	23,222		22,905
– of which external employees	1,749	2,699		1,656
1. Annualised profit/(loss) for the period, excluding payments attributable to AT1 capital securities and results attributable to non-controlling interests, divided by the average equity attributable to the equity holders of the parent company excluding AT1 capital securities.
2. Profit/(loss) for the period, excluding payments attributable to AT1 capital securities and results attributable to non-controlling interests, divided by the average number of outstanding and paid-up ordinary shares.
3. For Q3 2026, the average number of outstanding shares amounted to 814,935,713 (Q2 2026: 817,435,155; Q3 2025: 829,140,682). As at 30 September 2026, the average number of outstanding shares amounted to 818,490,711 (30 September 2025: 831,745,938).

Attachments

• ABN AMRO Bank – Quarterly Report third quarter 2026
• 20261111 ABN AMRO posts net profit of € 940 million in Q3 2026

Martela Corporation, Interim Report, 11.11.2026, at 08:00 a.m.

The revenue and operating result for January-September 2026 decreased compared to the same period of the previous year.

July–September 2026 

• Revenue was EUR 11.8 million (20.7), representing a change of -42.8%
• Comparable operating result was EUR -1.0 million (0.3)
• Operating result was EUR -0.8 million (0.3)
• Operating profit per revenue was -6.9% (1.3)
• The result for the period was EUR -1.4 million (-0.4)
• Earnings per share amounted to EUR -0.30 (-0.09)

January–September 2026 

• Revenue was EUR 43.8 million (70.9), representing a change of -38.2%
• Comparable operating result was EUR -4.5 million (-1.2)
• Operating result was EUR -3.2 million (-1.2)
• Operating profit per revenue was -7.3% (-1.6)
• The result for the period was EUR -4.8 million (-2.9)
• Earnings per share amounted to EUR -1.04 (-0.63)

Outlook

Outlook for 2026

Martela Group’s full-year revenue for 2026 is estimated to amount to approximately EUR 66–73 million.
The comparable operating result is estimated to be negative by EUR 1–3 million.

Key figures, EUR million

	2026	2025	Change	2026	2025	Change	2025
	7-9	7-9	%	1-9	1-9	%	1-12
Revenue	11.8	20.7	-42.8%	43.8	70.9	-38.2%	93.7
Operating result	-0.8	0.3	-402.6%	-3.2	-1.2		-1.1
Operating result %	-6.9%	1.3%		-7.3%	-1.6%		-1.1%
Result before taxes	-1.2	-0.3	280.6%	-4.5	-2.7		-3.2
Result for the period	-1.4	-0.4	225.6%	-4.8	-2.9		-3.5
Earnings/share, EUR	-0.30	-0.09	231.36%	-1.04	-0.63		-0.75
Return on investment %	-23.9	-5.8		-22.8	-5.2		-5.1
Return on equity % *)	n/a	n/a		n/a	n/a		n/a
Equity ratio %				-26.3	-3.8		-5.1
Gearing % **)				neg.	neg.		neg.

*) Return on equity has not been informed for the review period, because the average equity of the rewiev period was negative.
**) Gearing was negative because equity was negative.
Panu Ala-Nikkola, CEO:

“During the review period, demand was considerably weaker than expected, particularly in Finland and Sweden. Customer uncertainty, postponements of projects and the decrease in average project size were reflected in both order intake and revenue. In particular, the market for large office projects was significantly below the level of the corresponding period of the previous year. Deliveries are expected to increase during the fourth quarter. In addition, some deliveries originally scheduled for the review period have been postponed to the fourth quarter.

Our revenue in January–September was EUR 43.8 million, which was 38.2% lower than in the corresponding period of the previous year. Comparable revenue, taking into account the divestment of the moving services business, decreased by 34%. Revenue decreased in all market areas compared with the corresponding period of the previous year. Our revenue in July–September was weak at EUR 11.8 million, which was 42.8% lower than in the corresponding period of the previous year. Comparable revenue, taking into account the divestment of the moving services business, decreased by 33%.

The Group’s total new orders decreased by approximately 29% during the review period compared with the corresponding period of the previous year. Orders decreased in all Nordic countries during the review period but increased in export markets outside the Nordic countries. At the end of the review period, the order backlog was approximately 4% higher than in the corresponding period of the previous year, and we therefore expect deliveries in the final quarter of the year to be clearly higher than in the previous quarters.

Our comparable operating result weakened during the review period compared with the corresponding period of the previous year and amounted to EUR -4.5 million (-1.2). In July–September, the comparable operating result was EUR -1.0 million (+0.3). The main reason for the negative operating result was the significant decrease in delivery volumes. We succeeded in improving the efficiency of both our operational and administrative activities, but the impact of these measures was not sufficient to compensate for the significant decrease in revenue.

In September, the Extraordinary General Meeting resolved to carry out a share issue. Share issue was carried out in early October and generated gross proceeds of approximately EUR 7.2 million. I would like to thank all our shareholders for their confidence in the company’s future. The company’s objective is to improve its competitiveness, profitability and cash flow. Measures already implemented and planned will help us adapt to lower volumes and fluctuations in demand, with their full impact expected to be seen in 2027. Key measures include, among other things, streamlining and developing the product portfolio, increasing our focus on soundproof work and meeting pods, growing the WaaS (‘Workplace as a Service’) business model, shifting towards more order-driven production, and further reducing administrative and premises-related costs.

The need for work and learning environments has not disappeared. Customer needs are constantly evolving, creating demand also in the future. Martela is well positioned to respond to these needs, and further sharpening our product portfolio and concepts will remain at the core of our operations. The company has a focused organisation, a competitive offering, strong customer relationships and extensive experience in the industry. We are now building the next phase of the company.”

Market situation

The general market situation in the office sector continued to be more challenging than expected in the Nordic countries. The office property market remained subdued, and vacancy rates in 2026 have, on average, been slightly higher than in the previous year. Significant uncertainties continue to surround both the general economic situation and customer demand for office-related investments. The geopolitical and trade policy environment is contributing to uncertainty and also affects the outlook for interest rates and inflation. For 2026, we do not expect a significant strengthening of demand. The continued intense competitive environment is also placing pressure on margin development in certain customer segments.
For 2027, we expect the office property market to strengthen slightly. However, the outlook remains subject to significant uncertainty and regional variation.

Changes in ways of working continue to create a need for changes in workspaces. In addition, we continue to believe that the relative share of on-site work will increase from its current level, particularly in Martela’s main markets in the Nordic countries. As the above-mentioned needs materialise, they will support long-term demand for Martela’s services and furniture.

BRIEFING

A briefing will not be held, but additional information can be asked by telephone from CEO Panu Ala-Nikkola and CFO Henri Berg on Wednesday November 11, 2026 from 12 noon to 2 p.m. EET.

Martela Corporation
Board of Directors

Panu Ala-Nikkola
CEO

Further information
Panu Ala-Nikkola, CEO, +358 50 502 4728
Henri Berg, CFO, +358 40 836 5464

Distribution
Nasdaq Helsinki
Key news media

www.martela.com

Martela is a Nordic leader specialising in user-centric working and learning environments. With over 80 years of experience, we create the best places to work and offer our customers the Martela Lifecycle solutions which combine furniture and related services into a seamless whole.

Attachment

• 2026_1111 Interim Report

MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the pricing of its previously announced underwritten public offering of its common stock, comprised of 18,750,000 shares of common stock at a public offering price of $1.60 per share. The gross proceeds to the Company from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

The Company also granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares in the offering are being sold by the Company. The Company intends to use a portion of the net proceeds from this offering to repay a portion of the outstanding term loan under the Company’s Credit Agreement and Guaranty, as amended, with Perceptive Credit Holdings IV, LP (the “Credit Facility”), and for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures. The offering is expected to close on or about November 12, 2026, subject to the satisfaction of customary closing conditions.

As previously disclosed, on November 5, 2026, the Company entered into an Amendment No. 6 to the Credit Facility (the “Perceptive Sixth Amendment”), which amends the Credit Facility to, among other things, reduce certain revenue covenants, subject to certain conditions precedent, including, among other things, a prepayment of no less than $15,000,000, together with accrued but unpaid interest and the applicable early prepayment fee, plus the applicable amendment fee and payment of the lender parties’ other costs and expenses. If such conditions are not satisfied or waived on or before November 30, 2026, the Perceptive Sixth Amendment will automatically terminate. The Company anticipates that, if the conditions precedent in the Perceptive Sixth Amendment are satisfied, the reduction of those revenue covenants will resolve the going concern risk referenced in the Company’s recent Form 10-Q filings.

William Blair is acting as the lead bookrunning manager for the offering. BTIG and Canaccord Genuity are acting as additional bookrunners for the offering.

A shelf registration statement relating to the common stock being sold in this offering was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 3, 2025, and was declared effective on July 18, 2025. The offering is being made only by means of a prospectus supplement and the accompanying prospectus that form part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering and accompanying prospectus has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and accompanying prospectus can be obtained from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Neuronetics

Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar Advanced Therapy System, the Company is a leading provider of transcranial magnetic stimulation (“TMS”) treatment and, through Greenbrook TMS Inc. (“Greenbrook”), operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder (“MDD”) in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.¹

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.

Safe Harbor / Forward-Looking Statements

Certain statements in this press release include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. Forward-looking statements in this press release include, but are not limited to, statements regarding the filing of the final prospectus supplement and the accompanying prospectus relating to the offering, anticipated closing of the offering, the gross proceeds, the intended use of proceeds, including the prepayment of a portion of the outstanding term loan under the Credit Facility with Perceptive Credit Holdings IV, LP, the satisfaction of the conditions precedent to the effectiveness of the Perceptive Sixth Amendment, and the completion of the offering on the anticipated terms or at all. There can be no assurance that this offering will close or that the Company will receive the net proceeds therefrom. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those projected, including the anticipated timing of the offering, market conditions and satisfaction of customary closing conditions for the offering and our ability to satisfy the conditions precedent to the Perceptive Sixth Amendment on or before November 30, 2026. Other risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products and services; developments in respect of competing technologies and therapies for the indications that our products and services treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our self-sustainability; existing cash balance; our ability to achieve positive cash flows; and our ability to continue as a going concern. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. For a discussion of these and other related risks, please refer to the Company’s recent filings with the U.S. Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.

Investor Contact:

Mark Klausner
ICR Healthcare
443-213-0499 
ir@neuronetics.com

Media Contact:

EvolveMKD
646-517-4220 
NeuroStar@evolvemkd.com

MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the pricing of its previously announced underwritten public offering of its common stock, comprised of 18,750,000 shares of common stock at a public offering price of $1.60 per share. The gross proceeds to the Company from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

The Company also granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares in the offering are being sold by the Company. The Company intends to use a portion of the net proceeds from this offering to repay a portion of the outstanding term loan under the Company’s Credit Agreement and Guaranty, as amended, with Perceptive Credit Holdings IV, LP (the “Credit Facility”), and for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures. The offering is expected to close on or about November 12, 2026, subject to the satisfaction of customary closing conditions.

As previously disclosed, on November 5, 2026, the Company entered into an Amendment No. 6 to the Credit Facility (the “Perceptive Sixth Amendment”), which amends the Credit Facility to, among other things, reduce certain revenue covenants, subject to certain conditions precedent, including, among other things, a prepayment of no less than $15,000,000, together with accrued but unpaid interest and the applicable early prepayment fee, plus the applicable amendment fee and payment of the lender parties’ other costs and expenses. If such conditions are not satisfied or waived on or before November 30, 2026, the Perceptive Sixth Amendment will automatically terminate. The Company anticipates that, if the conditions precedent in the Perceptive Sixth Amendment are satisfied, the reduction of those revenue covenants will resolve the going concern risk referenced in the Company’s recent Form 10-Q filings.

William Blair is acting as the lead bookrunning manager for the offering. BTIG and Canaccord Genuity are acting as additional bookrunners for the offering.

A shelf registration statement relating to the common stock being sold in this offering was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 3, 2025, and was declared effective on July 18, 2025. The offering is being made only by means of a prospectus supplement and the accompanying prospectus that form part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering and accompanying prospectus has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and accompanying prospectus can be obtained from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Neuronetics

Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar Advanced Therapy System, the Company is a leading provider of transcranial magnetic stimulation (“TMS”) treatment and, through Greenbrook TMS Inc. (“Greenbrook”), operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder (“MDD”) in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.¹

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.

Safe Harbor / Forward-Looking Statements

Certain statements in this press release include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. Forward-looking statements in this press release include, but are not limited to, statements regarding the filing of the final prospectus supplement and the accompanying prospectus relating to the offering, anticipated closing of the offering, the gross proceeds, the intended use of proceeds, including the prepayment of a portion of the outstanding term loan under the Credit Facility with Perceptive Credit Holdings IV, LP, the satisfaction of the conditions precedent to the effectiveness of the Perceptive Sixth Amendment, and the completion of the offering on the anticipated terms or at all. There can be no assurance that this offering will close or that the Company will receive the net proceeds therefrom. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those projected, including the anticipated timing of the offering, market conditions and satisfaction of customary closing conditions for the offering and our ability to satisfy the conditions precedent to the Perceptive Sixth Amendment on or before November 30, 2026. Other risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products and services; developments in respect of competing technologies and therapies for the indications that our products and services treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our self-sustainability; existing cash balance; our ability to achieve positive cash flows; and our ability to continue as a going concern. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. For a discussion of these and other related risks, please refer to the Company’s recent filings with the U.S. Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.

Investor Contact:

Mark Klausner
ICR Healthcare
443-213-0499 
ir@neuronetics.com

Media Contact:

EvolveMKD
646-517-4220 
NeuroStar@evolvemkd.com

MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the pricing of its previously announced underwritten public offering of its common stock, comprised of 18,750,000 shares of common stock at a public offering price of $1.60 per share. The gross proceeds to the Company from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

The Company also granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares in the offering are being sold by the Company. The Company intends to use a portion of the net proceeds from this offering to repay a portion of the outstanding term loan under the Company’s Credit Agreement and Guaranty, as amended, with Perceptive Credit Holdings IV, LP (the “Credit Facility”), and for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures. The offering is expected to close on or about November 12, 2026, subject to the satisfaction of customary closing conditions.

As previously disclosed, on November 5, 2026, the Company entered into an Amendment No. 6 to the Credit Facility (the “Perceptive Sixth Amendment”), which amends the Credit Facility to, among other things, reduce certain revenue covenants, subject to certain conditions precedent, including, among other things, a prepayment of no less than $15,000,000, together with accrued but unpaid interest and the applicable early prepayment fee, plus the applicable amendment fee and payment of the lender parties’ other costs and expenses. If such conditions are not satisfied or waived on or before November 30, 2026, the Perceptive Sixth Amendment will automatically terminate. The Company anticipates that, if the conditions precedent in the Perceptive Sixth Amendment are satisfied, the reduction of those revenue covenants will resolve the going concern risk referenced in the Company’s recent Form 10-Q filings.

William Blair is acting as the lead bookrunning manager for the offering. BTIG and Canaccord Genuity are acting as additional bookrunners for the offering.

A shelf registration statement relating to the common stock being sold in this offering was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 3, 2025, and was declared effective on July 18, 2025. The offering is being made only by means of a prospectus supplement and the accompanying prospectus that form part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering and accompanying prospectus has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and accompanying prospectus can be obtained from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Neuronetics

Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar Advanced Therapy System, the Company is a leading provider of transcranial magnetic stimulation (“TMS”) treatment and, through Greenbrook TMS Inc. (“Greenbrook”), operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder (“MDD”) in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.¹

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.

Safe Harbor / Forward-Looking Statements

Certain statements in this press release include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. Forward-looking statements in this press release include, but are not limited to, statements regarding the filing of the final prospectus supplement and the accompanying prospectus relating to the offering, anticipated closing of the offering, the gross proceeds, the intended use of proceeds, including the prepayment of a portion of the outstanding term loan under the Credit Facility with Perceptive Credit Holdings IV, LP, the satisfaction of the conditions precedent to the effectiveness of the Perceptive Sixth Amendment, and the completion of the offering on the anticipated terms or at all. There can be no assurance that this offering will close or that the Company will receive the net proceeds therefrom. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those projected, including the anticipated timing of the offering, market conditions and satisfaction of customary closing conditions for the offering and our ability to satisfy the conditions precedent to the Perceptive Sixth Amendment on or before November 30, 2026. Other risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products and services; developments in respect of competing technologies and therapies for the indications that our products and services treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our self-sustainability; existing cash balance; our ability to achieve positive cash flows; and our ability to continue as a going concern. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. For a discussion of these and other related risks, please refer to the Company’s recent filings with the U.S. Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.

Investor Contact:

Mark Klausner
ICR Healthcare
443-213-0499 
ir@neuronetics.com

Media Contact:

EvolveMKD
646-517-4220 
NeuroStar@evolvemkd.com

MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the pricing of its previously announced underwritten public offering of its common stock, comprised of 18,750,000 shares of common stock at a public offering price of $1.60 per share. The gross proceeds to the Company from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

The Company also granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares in the offering are being sold by the Company. The Company intends to use a portion of the net proceeds from this offering to repay a portion of the outstanding term loan under the Company’s Credit Agreement and Guaranty, as amended, with Perceptive Credit Holdings IV, LP (the “Credit Facility”), and for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures. The offering is expected to close on or about November 12, 2026, subject to the satisfaction of customary closing conditions.

As previously disclosed, on November 5, 2026, the Company entered into an Amendment No. 6 to the Credit Facility (the “Perceptive Sixth Amendment”), which amends the Credit Facility to, among other things, reduce certain revenue covenants, subject to certain conditions precedent, including, among other things, a prepayment of no less than $15,000,000, together with accrued but unpaid interest and the applicable early prepayment fee, plus the applicable amendment fee and payment of the lender parties’ other costs and expenses. If such conditions are not satisfied or waived on or before November 30, 2026, the Perceptive Sixth Amendment will automatically terminate. The Company anticipates that, if the conditions precedent in the Perceptive Sixth Amendment are satisfied, the reduction of those revenue covenants will resolve the going concern risk referenced in the Company’s recent Form 10-Q filings.

William Blair is acting as the lead bookrunning manager for the offering. BTIG and Canaccord Genuity are acting as additional bookrunners for the offering.

A shelf registration statement relating to the common stock being sold in this offering was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 3, 2025, and was declared effective on July 18, 2025. The offering is being made only by means of a prospectus supplement and the accompanying prospectus that form part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering and accompanying prospectus has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and accompanying prospectus can be obtained from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Neuronetics

Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar Advanced Therapy System, the Company is a leading provider of transcranial magnetic stimulation (“TMS”) treatment and, through Greenbrook TMS Inc. (“Greenbrook”), operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder (“MDD”) in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.¹

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.

Safe Harbor / Forward-Looking Statements

Certain statements in this press release include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws. Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions. Forward-looking statements in this press release include, but are not limited to, statements regarding the filing of the final prospectus supplement and the accompanying prospectus relating to the offering, anticipated closing of the offering, the gross proceeds, the intended use of proceeds, including the prepayment of a portion of the outstanding term loan under the Credit Facility with Perceptive Credit Holdings IV, LP, the satisfaction of the conditions precedent to the effectiveness of the Perceptive Sixth Amendment, and the completion of the offering on the anticipated terms or at all. There can be no assurance that this offering will close or that the Company will receive the net proceeds therefrom. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those projected, including the anticipated timing of the offering, market conditions and satisfaction of customary closing conditions for the offering and our ability to satisfy the conditions precedent to the Perceptive Sixth Amendment on or before November 30, 2026. Other risks and uncertainties include, without limitation, risks and uncertainties related to: the effect of the transaction with Greenbrook on our business relationships; operating results and business generally; our ability to execute our business strategy; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; our ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products and services; developments in respect of competing technologies and therapies for the indications that our products and services treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; potential effects of evolving and/or extensive government regulation; the terms of our credit facility; our self-sustainability; existing cash balance; our ability to achieve positive cash flows; and our ability to continue as a going concern. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. For a discussion of these and other related risks, please refer to the Company’s recent filings with the U.S. Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov, including, without limitation, the factors described under the heading “Risk Factors” in Neuronetics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as may be updated or supplemented by subsequent reports that Neuronetics has filed or files with the SEC. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or changes in the Company’s expectations.

Investor Contact:

Mark Klausner
ICR Healthcare
443-213-0499 
ir@neuronetics.com

Media Contact:

EvolveMKD
646-517-4220 
NeuroStar@evolvemkd.com

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock at a public offering price of $3.50 per share. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 5,357,142 shares of its common stock. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares of common stock in the offering are to be sold by Prime Medicine. The offering is expected to close on or about November 12, 2026, subject to the satisfaction of customary closing conditions.

Jefferies, TD Cowen and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. Oppenheimer & Co. and LifeSci Capital are acting as passive book-running managers for the offering.

The shares of common stock are being offered by Prime Medicine pursuant to a shelf registration statement on Form S-3ASR (File No. 333-291348) filed with the U.S. Securities and Exchange Commission (SEC) on November 7, 2025, as amended by that certain Post-Effective Amendment No. 1 to Form S-3 (No. 333-291348) and that certain Post-Effective Amendment No. 2 to Form S-3 (No. 333-291348), each filed with the SEC on March 3, 2026, and declared effective by the SEC on March 4, 2026. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov.

The final prospectus supplement relating to and describing the final terms of the offering will be filed with the SEC and, when available, may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Prime Medicine

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications.

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around its core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high-value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path.

© 2026 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine’s beliefs and expectations regarding: the expected gross proceeds from the public offering and the timing and closing of the public offering. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Prime Medicine’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and any of its subsequent filings with the SEC. In addition, any forward-looking statements represent Prime Medicine’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor and Media Contacts

Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com

Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com

Record third quarter revenue and Adjusted EBITDA exceed outlook; 2026 outlook¹ updated to include revenue growth of approximately 37% and Adjusted EBITDA growth of approximately 37%

THIRD QUARTER 2026 HIGHLIGHTS

• Revenue increased 49% year-over-year to $461.5 million
• Net loss attributable to ITG, Inc. of $6.1 million
• Adjusted EBITDA² increased 64% year-over-year to $64.5 million
• Free Cash Flow² of $62.8 million versus $26.2 million in Q3 2025
• NTM Backlog³ of $1,539 million as of September 30, 2026, compared to $1,209 million as of September 30, 2025 and $1,517 million as of June 30, 2026, supporting strong revenue visibility
• Strong new order activity, including broadband fiber deployment awards with multiple new customers
• Record levels in the quarter for Revenue, Adjusted EBITDA and NTM Backlog

1. Statements related to our  full-year 2026 financial outlook are forward-looking, and actual results may differ materially. Refer to the “Forward Looking Statements” in the Appendix of this document for information on the factors that could cause our actual results to differ materially from these forward-looking statements.
2. Non-GAAP measure – Refer to the Appendix of this document for discussion of non-GAAP measures, reconciliations of these measures to the most directly comparable U.S. GAAP measure and a discussion of why management believes these non-GAAP measures are useful.  As discussed below, ITG is not providing reconciliations of forward-looking non-GAAP measures because such reconciliations are not available without unreasonable effort.
3. Next Twelve Month (NTM) Backlog represents total committed future revenue over the next twelve months supported by executed contracts, historical activity levels, customer guidance, and / or management estimates. Timing for revenue from projects included in NTM Backlog is subject to change based on a number of factors. Actual results may differ materially.

FORT LAUDERDALE, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) — ITG, Inc. (Nasdaq: ITG) (“ITG” or “the Company”), a leading provider of end-to-end services to the digital infrastructure industry, today announced financial results for its third quarter ended September 30, 2026.

“Our third quarter results demonstrate the continued strength of the business and our ability to execute efficiently for customers even as activity increased substantially in the period,” said Andy Parrott, Chief Executive Officer of ITG. “Revenue and Adjusted EBITDA reached record levels and exceeded the outlook we provided last quarter. Adjusted EBITDA margin also improved both year-over-year and sequentially, reflecting higher activity levels, improved asset utilization and solid execution by our operating teams.”

“Demand remains broadly healthy across our communications and digital infrastructure markets, with particular strength in broadband wireline infrastructure deployment. We continue to expand our work with both newer and long-standing customers and leverage growth opportunities created by significant customer investment in broadband, network upgrades and data center connectivity. Our broad turnkey services, national operating model and ability to support customers across both new installation and full lifecycle services position us well as a leading service provider for our customers.”

“We enter the fourth quarter with substantial revenue visibility and are actively exploring opportunities for partnerships with new customers, including several new wins confirmed in September. Our priorities remain focused on executing for our customers, converting awarded work into profitable revenue, improving cash conversion and focusing on disciplined capital allocation. Our updated outlook reflects our confidence in the business and our expectations for continued profitable growth,” Mr. Parrott concluded.

2026 FINANCIAL OUTLOOK⁽¹⁾
(in millions, except margin, effective tax rate, CapEx)

	Q4 2026	YoY Growth(2)		FY 2026	YoY Growth(2)
Revenue	$378	+15%		$1,578	+37%
Adjusted Net Income(3)	NM	NM		NM	NM
Adjusted EBITDA(3)	$51	+31%		$203	+37%
Adjusted EBITDA Margin(3)	13.4%	+170 bps		12.9%	+10 bps
Forecast Assumptions
Effective Tax Rate				NM
CapEx (% of Revenue)				~3.9%
Net Interest Expense				~$72
Depreciation Expense				~$53
Amortization Expense				~$33
Diluted Shares Outstanding				~48.5

_____________________

(1)	Statements related to our full-year 2026 financial outlook are forward-looking, and actual results may differ materially. Refer to the “Forward Looking Statements” in the Appendix of this document for information on the factors that could cause our actual results to differ materially from these forward-looking statements.
(2)	Represents year-over-year growth compared to the prior year period. “bps” represents basis points of change on percentage data.
(3)	Non-GAAP measures – Refer to the Appendix of this document for discussion of non-GAAP measures, reconciliations of these measures to the most directly comparable U.S. GAAP measure and a discussion of why management believes these non-GAAP measures are useful.  As discussed below, ITG is not providing reconciliations of forward-looking non-GAAP measures because such reconciliations are not available without unreasonable effort.

THIRD QUARTER 2026 COMMENTARY

ITG has posted its Third Quarter 2026 Commentary on the Investors section of ITG’s website at ir.itgcomm.com. This document provides detailed commentary on ITG’s third quarter 2026 financial and operating performance, business trends and outlook and should be reviewed in conjunction with the earnings release and conference call.

CONFERENCE CALL INFORMATION

ITG will host a webcast of its quarterly earnings call to discuss these results on November 11, 2026, at 8:00 a.m. ET, which can be accessed through the Investors section of ITG’s website at ir.itgcomm.com. A replay of the webcast also will be available following the live event.

ABOUT ITG, INC.

ITG is a leading provider of end-to-end services to the communications and digital infrastructure industries throughout the United States. ITG supports the planning, design, construction, operation, maintenance, and expansion of broadband, wireless, data center, utility, and civil infrastructure. With a workforce operating across 49 states, ITG is positioned to build and maintain the digital backbone powering our future.

APPENDIX

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on our management’s beliefs and assumptions and on information currently available to our management. These statements include, but are not limited to, statements regarding our expectations of future performance, including guidance for our revenue, Adjusted Net Income, Adjusted EBITDA and Adjusted EBITDA Margin for the fourth quarter and fiscal year ending December 31, 2026, and our NTM Backlog as of September 30, 2026.  Forward-looking statements can be identified by terms such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “predict”, “project”, “seek”, “should”, “will”, “would” or similar expressions and the negatives of those terms. Such statements are not historical facts but rather are based on the Company’s current expectations or beliefs concerning future events. Forward-looking statements involve known and unknown risks, uncertainties and other factors, that may cause our actual results to be materially different from any future results contemplated by the forward-looking statements, including those described in the registration statements and periodic reports the Company files with the Securities and Exchange Commission (the “SEC”), including the Company’s final prospectus dated June 30, 2026 and filed with the SEC on July 2, 2026. Given these uncertainties, you should not place undue reliance on forward-looking statements. Any forward-looking statement speaks only as of the date on which it was made, and the Company does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in the Company’s registration statements and periodic reports.

Non-GAAP Financial Measures

This press release includes certain financial measures that are not calculated in accordance with generally accepted accounting principles in the United States (“GAAP”), including Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted Net Income. Management uses these non-GAAP financial measures to evaluate the Company’s operating performance, cash generation, liquidity, leverage profile and ability to execute its strategic priorities. The Company believes these measures provide useful supplemental information to investors in evaluating period-to-period operating performance and financial position.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in accordance with GAAP. These measures may not be comparable to similarly titled measures used by other companies. Reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure are provided below.

The Company is providing guidance for certain non-GAAP financial measures, including Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted Net Income. The Company is not providing quantitative reconciliations of these forward-looking non-GAAP measures to the most directly comparable GAAP measures due to the uncertainty and inherent difficulty of predicting certain items that affect GAAP results, including, as applicable, acquisition-related costs, stock-based compensation, changes in working capital, interest expense, depreciation and amortization, tax impacts, and other items that may be material and difficult to forecast.  Accordingly, a reconciliation is not available without unreasonable effort. The variability of these items could have a significant impact on the Company’s future GAAP financial results.

FINANCIAL STATEMENTS

ITG Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Revenue	$	461,528			$	309,174			$	1,200,083			$	826,966
Cost of Revenue, Excluding Depreciation and Amortization		375,626				252,950				989,273				676,646
Selling, General and Administrative		39,696				20,626				93,409				51,172
Depreciation and Amortization		21,880				15,106				63,319				42,351
Change in Fair Value of Contingent Liabilities		200				1,467				2,386				1,804
		437,402				290,149				1,148,387				771,973
Interest expense		(19,880	)			(15,920	)			(57,639	)			(29,665	)
Other expense, net		(1,479	)			(1,054	)			(3,407	)			(3,085	)
Income (Loss) Before Provision for Income Taxes		2,767				2,051				(9,350	)			22,243
Provision for income taxes		2,239				1,224				1,492				8,237
Net income (loss)		528				827				(10,842	)			14,006
Less: net income attributable to non-controlling interests		6,677				—				6,677				—
Net income (loss) attributable to ITG, Inc.	$	(6,149	)		$	827			$	(17,519	)		$	14,006

ITG Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, unaudited)
	September 30, 2026			December 31, 2025
ASSETS
Current Assets:
Cash and cash equivalents	$	160		$	3,719
Accounts receivable, net		183,110			141,314
Contract assets		369,791			222,094
Prepaid expenses and other current assets		29,640			17,310
Total current assets		582,701			384,437
Property and Equipment, Net		177,225			158,492
Operating Lease Right-of-Use Assets		30,332			27,926
Finance Lease Right-of-Use Assets		2,037			3,019
Goodwill		195,038			187,748
Intangible Assets, Net		188,512			211,383
Deferred Tax Assets		45,633			—
Other Long-Term Assets		—			2,832
Total Assets	$	1,221,478		$	975,837
LIABILITIES AND EQUITY
Current Liabilities:
Accounts payable	$	75,107		$	41,221
Accrued expenses		66,006			57,245
Current portion of operating lease obligations		11,883			10,969
Current portion of finance lease obligations		1,275			1,221
Current portion of equipment loans		24,902			22,493
Current portion of term loans		—			16,500
Total current liabilities		179,173			149,649
Equipment Loans, Net		85,331			65,804
Revolving Line of Credit		77,000			30,000
Term Loans, Net		411,885			623,463
Operating Lease Obligations, Net		19,170			17,608
Finance Lease Obligations, Net		908			1,905
Payables Pursuant to the Tax Receivable Agreement		50,163			—
Other Long-Term Liabilities		—			7,100
Contingent Liabilities		18,036			20,088
Deferred Tax Liability		15,393			16,475
Total liabilities		857,059			932,092
Commitments and Contingencies
Equity:
Members’ equity		—			43,745
Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued nor outstanding		—			—
Class A common stock, $0.001 par value; 1,000,000,000 shares authorized; 48,465,158 issued and outstanding as of September 30, 2026		48			—
Class B common stock, $0.001 par value; 200,000,000 shares authorized; 75,712,686 issued and outstanding as of September 30, 2026		76			—
Additional paid-in capital		126,681			—
Retained earnings		3,000			—
Accumulated Other Comprehensive Income		—			—
Total equity attributable to ITG, Inc. / ITG Parent		129,805			43,745
Non-controlling interests		234,614			—
Total equity		364,419			43,745
Total Liabilities and Equity	$	1,221,478		$	975,837

ITG Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, unaudited)
	Nine Months Ended September 30,
	2026				2025
Cash Flows from Operating Activities:
Net (loss) income	$	(10,842	)		$	14,006
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation		38,548				21,004
Amortization of intangible assets		24,771				21,347
Amortization/ write-off of discounts and deferred financing costs		9,885				2,266
Amortization of operating right of use assets		12,678				7,171
Deferred income taxes		(2,434	)			(3,402	)
Loss (gain) on sale of assets		226				(155	)
Change in fair value of contingent liabilities		2,386				1,804
Equity-based compensation		12,639				2,751
Changes in assets and liabilities, net of business acquisitions:
Accounts receivable		(32,852	)			(18,236	)
Contract assets		(147,697	)			(30,510	)
Prepaid expenses and other current assets		(13,042	)			(965	)
Accounts payable and accrued expenses		30,984				16,847
Operating lease liabilities		(11,626	)			(7,035	)
Payments of contingent liabilities		(3,022	)			—
Net cash (used in) provided by operating activities		(89,398	)			26,893
Cash Flows from Investing Activities:
Purchase of property and equipment		(17,761	)			(41,773	)
Proceeds from sale of property and equipment		1,666				1,874
Acquisitions, net of cash acquired		(18,440	)			(50,921	)
Net cash used in investing activities		(34,535	)			(90,820	)
Cash Flows from Financing Activities:
Proceeds from issuance of Class A common stock sold in an IPO, net of underwriting discounts and commissions		339,309				—
Payments of offering costs		(14,211	)			—
Payments of acquisition amounts due to sellers		(5,037	)			(15,000	)
Payments of contingent liabilities		(1,416	)			—
Proceeds from long-term debt		19,056				30,788
Payments on long-term debt		(25,795	)			(11,202	)
Proceeds from term loans		—				617,750
Payments made on term loans		(237,251	)			(291,719	)
Proceeds from line of credit		606,000				179,200
Payments made on line of credit		(559,000	)			(179,200	)
Payments on finance leases		(943	)			(379	)
Repurchase of units		—				(7,065	)
Distributions to members		(338	)			(226,000	)
Payments of debt costs		—				(22,200	)
Net cash provided by financing activities		120,374				74,973
Net (decrease) increase in cash and cash equivalents		(3,559	)			11,046
Cash and cash equivalents – beginning of period		3,719				7,367
Cash and cash equivalents – end of period	$	160			$	18,413
Supplemental disclosures of cash flow information:
Cash paid for interest	$	57,248			$	21,819
Cash paid for taxes, net of refunds	$	1,602			$	6,407
Supplemental disclosures of noncash investing and financing activity:
Deemed contribution related to tax receivable agreement	$	5,883			$	—
Recording of deferred tax assets related to ITG Blocker Merger	$	33,724			$	—
Recording of amounts payable pursuant to tax receivable agreement	$	50,163			$	—
Accrued capital expenditures	$	8,587			$	—
ROU liabilities from ROU asset acquisitions	$	14,102			$	13,153
Measurement period adjustment to goodwill and property and equipment	$	2,142			$	—
Property and equipment acquired through equipment loans	$	28,675			$	17,099

Non-GAAP Financial Measures & Reconciliations

Adjusted EBITDA and Free Cash Flow Reconciliation

The following table reconciles net income, the most directly comparable financial measure presented in accordance with GAAP, to Adjusted EBITDA and Free Cash Flow, and calculations of Adjusted EBITDA Margin and Free Cash Flow Conversion as follows (in thousands, except percentages):

	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
	2026				2025				2026				2025
Net income (loss)	$	528			$	827			$	(10,842	)		$	14,006
Interest expense, net		19,880				15,920				57,639				29,665
Income tax expense (benefit)		2,239				1,224				1,492				8,237
Depreciation expense		13,604				7,964				38,548				21,004
Amortization of intangibles		8,276				7,142				24,771				21,347
Other expenses, net		1,479				1,054				3,407				3,085
Equity-based compensation		10,300				1,480				12,639				2,751
Transaction costs(1)		1,292				1,818				5,331				3,438
Restructuring, integration, and business optimization costs(2)		6,744				437				17,730				4,479
Change in fair value of contingent liabilities(3)		200				1,467				2,386				1,804
Adjusted EBITDA	$	64,542			$	39,333			$	153,101			$	109,816
Adjusted EBITDA Margin		14.0	%			12.7	%			12.8	%			13.3	%
Purchase of property and equipment	$	1,792			$	13,146			$	17,761			$	41,773
Free Cash Flow	$	62,750			$	26,187			$	135,340			$	68,043
Free Cash Flow Conversion		97.2	%			66.6	%			88.4	%			62.0	%

                                                      

(1)	Represents professional, legal and advisory fees incurred in connection with acquisitions completed during the presented period.
(2)	Represents non-recurring expenses associated with the restructuring of management positions, start-up costs for new markets and service offerings and exiting locations that we do not expect will impact the go forward operations of the business.
(3)	Represents non-recurring earnout amounts accrued to certain sellers in connection with the acquisitions completed during the presented period.

INVESTOR CONTACT

629-282-9862
ir@itgcomm.com

PASCAGOULA, Miss., Nov. 10, 2026 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division and Supervisor of Shipbuilding, Conversion and Repair Gulf Coast (SUPSHIP GC) broke ground today on a new 101,000-square-foot customer support complex, reinforcing collaboration between the U.S. Navy and industry personnel supporting some of the nation’s most critical shipbuilding programs.

Funded through a partnership between the U.S. Navy and Ingalls Shipbuilding, the $50 million facility will primarily house SUPSHIP GC personnel currently located in Pascagoula. SUPSHIP GC administers Navy shipbuilding contracts across Mississippi, Louisiana and Alabama and includes more than 600 military and civilian personnel responsible for engineering, quality assurance, contract management and financial oversight throughout ship construction and delivery.

“Today’s groundbreaking represents an important investment in the future of Navy shipbuilding and in the partnerships that make our mission possible here at Ingalls,” said Eric Crooker, Ingalls vice president of program management. “By bringing our government partners together, we are strengthening collaboration, improving efficiency and enhancing our ability to deliver the high-quality ships our sailors depend on.”

Photos and a video accompanying this release are available at: https://www.hii.com/news/hii-and-navy-break-ground-on-new-customer-support-complex-at-ingalls-shipbuilding

Company leaders were joined at the groundbreaking by U.S. Navy representatives, Port of Pascagoula leadership, community stakeholders and elected officials to commemorate the start of construction.

Capt. Randy Slaff, U.S. Navy commanding officer of SUPSHIP GC said the new facility reflects the enduring partnership between the Navy and industry that is essential to delivering capability to the fleet.

“Our job at SUPSHIP is to collaborate with our industry partners and deliver warfighting capability to the Navy at speed,” said Capt. Slaff. “Anything that contributes to that core mission is vitally important and this building represents a direct investment in that effort. Shipbuilding is a national imperative, and this project will bring our team together under one roof, driving efficiency and strengthening alignment as we support shipbuilding across the Gulf Coast.”

Located on property leased from the Port of Pascagoula, the facility is scheduled for completion in June 2028 and expands the infrastructure supporting Navy shipbuilding activities at Ingalls and reinforces the longstanding partnership among industry, government and the local community.

As Mississippi’s largest manufacturing employer and a cornerstone of the nation’s shipbuilding industrial base, Ingalls continues to invest in the people, facilities and capabilities required to deliver critical warships to the U.S. Navy. The project reflects a shared commitment to workforce support, fleet readiness and the infrastructure required to meet future defense requirements.

About HII
HII is America’s Seapower Company. The nation’s largest shipbuilder, HII builds the manned and unmanned maritime systems and all-domain mission technologies that project U.S. and allied power around the world. With a more than 140-year history of advancing U.S. national security, HII is headquartered in Virginia and employs 46,000 people across three divisions. For more information, visit:

• HII on the web: https://www.HII.com/
• HII on Facebook: https://www.facebook.com/TeamHII
• HII on X: https://www.twitter.com/WeAreHII
• HII on Instagram: https://www.instagram.com/WeAreHII
• HII on LinkedIn: https://www.linkedin.com/company/wearehii

Contact:
Kimberly K. Aguillard
Kimberly.K.Aguillard@hii.com
228-355-5663

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4491611b-0a9c-4bd9-bc06-40027992ca56

-AtlasClearing Remains Compliant with Regulatory Net Capital Requirements as Correspondent Clearing and Onboarding Continue-

-Common Stock Expected to Be Quoted on the OTC Market Under “ATCH” During Appeal-

TAMPA, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (“AtlasClear” or the “Company”), a company building regulated financial infrastructure for smaller institutions, fintechs and advisors, today announced that on November 10, 2026, it was notified by NYSE American LLC (the “Exchange”) that the Exchange’s staff has suspended trading in the Company’s common stock, effective immediately, and has determined to commence proceedings to delist the common stock. The Exchange cited Section 1003(f)(v) of the NYSE American Company Guide, based on the low selling price of the common stock.

Key Takeaways

• AtlasClearing’s clearing operations continue in the ordinary course, and AtlasClearing remains compliant with its regulatory net capital requirements.
• The Exchange’s determination is based on the low selling price of the common stock, not on the Company’s operations or regulatory capital.
• AtlasClearing has signed eight correspondent broker-dealer agreements, and onboarding continues.
• The Company intends to appeal. During the appeal process, the common stock is expected to be quoted on the OTC market under the symbol “ATCH.”
• Shareholders continue to own their shares; the suspension does not change the number of shares held or shareholders’ percentage ownership.

The Company intends to appeal the staff’s determination by requesting a hearing before a Listing Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange, as permitted under Section 1203 of the NYSE American Company Guide. During the appeal process, the common stock will remain suspended from trading on the NYSE American and is expected to be quoted on the OTC market. The common stock remains listed on the NYSE American while the appeal is pending. The Exchange has stated that it will apply to the Securities and Exchange Commission to delist the common stock only upon completion of all applicable procedures, including any appeal by the Company. The Company currently intends to seek to effect a reverse stock split as one tool to support its appeal and continued listing. A reverse stock split would not, by itself, change shareholders’ percentage ownership of the Company.

The Exchange’s determination is based solely on the low selling price of the common stock. It does not relate to AtlasClearing’s regulatory capital compliance, the Company’s financial condition or the status of its correspondent clearing operations.

“Our underlying business remains operational, and our strategic priorities have not changed,” said John Schaible, Executive Chairman of AtlasClear Holdings. “We intend to pursue the appeal process and seek to restore trading on the NYSE American, while continuing to execute on our correspondent clearing strategy. AtlasClearing remains compliant with its regulatory capital requirements, and we believe the progress we are making in expanding our clearing platform is what will ultimately define the business.”

“Our correspondent clearing operations continue in the ordinary course, and our team remains focused on bringing additional firms onto the platform,” said Craig Ridenhour, President of AtlasClear Holdings and Chairman of AtlasClearing, Inc. “We have invested in the infrastructure, regulatory capabilities and personnel needed to support these relationships, and that work continues. On the operating side, our focus is on converting signed correspondent agreements into active clearing relationships and building a stronger, more diversified revenue base.”

Clearing Operations and Growth Strategy Continue

AtlasClear’s wholly owned subsidiary, AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.) (“AtlasClearing”), continues to operate its regulated clearing business and remains compliant with applicable net capital requirements. AtlasClearing has signed eight correspondent broker-dealer agreements, and the Company remains focused on expanding its correspondent clearing relationships, onboarding signed broker-dealer clients and developing its integrated financial infrastructure platform.

The Company continues to pursue its strategy of providing clearing and financial infrastructure services to smaller broker-dealers and financial institutions. Management remains focused on translating its growing correspondent network into active clearing activity, recurring revenue opportunities and long-term operating growth.

AtlasClear’s fiscal 2026 revenue increased 85% to $20.1 million, before material contributions from its newly signed correspondents, and cash more than doubled to $15.4 million without the use of an at-the-market offering or equity line.

Trading of Common Stock

The Company’s common stock remains issued and outstanding. During the appeal process, the Company expects its common stock to be quoted on the OTC market operated by OTC Markets Group under the symbol “ATCH.” The Company intends to continue to file reports with the Securities and Exchange Commission and to provide regular updates to shareholders, and holders’ ownership, voting rights and economic interests are unchanged. There can be no assurance that an active trading market will develop on the OTC market or that the appeal will be successful such that trading in the common stock will resume on the NYSE American.

The Company will file a Current Report on Form 8-K with the Securities and Exchange Commission disclosing the Exchange’s notice.

About AtlasClear Holdings, Inc.

AtlasClear Holdings, Inc. is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, its pending acquisition of Ark Financial Services, Inc., and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear Holdings seeks to deliver a vertically integrated suite of investment banking, brokerage, clearing, risk management, regulatory, and commercial banking solutions. For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the Company’s appeal of the Exchange’s determination, a potential reverse stock split, the quotation of its common stock on an over-the-counter market, the continuation of its business operations, the onboarding of correspondent broker-dealers and the Company’s growth strategy. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the outcome of any review of the Exchange’s determination; the delisting of the common stock and its effect on liquidity, the market price and the Company’s ability to raise capital; the effect of the suspension or delisting on the Company’s agreements, financing arrangements and pending transactions, including the pending acquisitions of Ark Financial Services, Inc. and Commercial Bancorp of Wyoming; delays in onboarding correspondent broker-dealers; and the other risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2026, and subsequent filings. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

Company Contact
AtlasClear Holdings, Inc.
Email: AtlasClearIR@atlasclear.com

Investor Relations Contact
Jeff Ramson, CEO
PCG Advisory, Inc.
Email: jramson@pcgadvisory.com